Hatch, S., Swift, L., Caporali, S., Carter, R., Hill, E., Macgregor, T., . . . Sharma, R. (2014). XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection.
Chicago-referens (17:e uppl.)Hatch, S., et al. XPF Protein Levels Determine Sensitivity of Malignant Melanoma Cells to Oxaliplatin Chemotherapy: Suitability as a Biomarker for Patient Selection. 2014.
MLA-referens (9:e uppl.)Hatch, S., et al. XPF Protein Levels Determine Sensitivity of Malignant Melanoma Cells to Oxaliplatin Chemotherapy: Suitability as a Biomarker for Patient Selection. 2014.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.